|Bid||76.50 x 1400|
|Ask||76.53 x 800|
|Day's Range||76.84 - 78.46|
|52 Week Range||53.22 - 78.47|
|Beta (5Y Monthly)||0.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.16 (2.85%)|
|Ex-Dividend Date||Mar 31, 2022|
|1y Target Est||N/A|
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.